Antimicrobial peptides for bacterial infections and their biomedical applications

Due to the rapid development of multidrug-resistant (MDR) bacteria due to the inappropriate use and misuse of antibiotics and the ineffective performance of antibiotics against refractory biofilm-associated infections (BRI), there is an urgent need for novel alternative antimicrobials and strategies to combat bacterial infections. Antimicrobial peptides (AMPs) have attracted considerable interest due to their potent activity against MDR pathogens and biofilm-associated infections, coupled with a substantially reduced risk of driving antimicrobial resistance-especially when employed as alternatives or adjuncts to conventional antibiotics. With the development of nanocarrier-based delivery strategies, AMP nanomaterials significantly improve the therapeutic effect of AMP by improving the hydrolytic stability, in vivo half-life, solubility, and reducing cytotoxicity and hemolysis of AMP. Distinct from previous reviews that primarily focus on AMP sequence engineering or generic nanocarrier types, this work adopts a clinically oriented framework organized by infection site-including pulmonary, bloodstream, gastrointestinal, chronic wound, and implant-associated infections. Key therapeutic outcomes reported in the literature are systematically compared, such as reductions in minimum inhibitory concentration (MIC), biofilm eradication efficiency, survival benefits in sepsis models, and wound closure kinetics. Formulation design strategies, administration routes, and the rational application of nanocarriers constructed from metallic elements, biocompatible polymers, and lipid-based architectures are discussed in the context of specific infectious microenvironments. By correlating the physicochemical properties of nanocarriers-such as surface charge, degradation profile, and release kinetics-with therapeutic performance across diverse infection models, this review also addresses the current limitations of AMP-based formulations in clinical applications. Overall, this review provides insights into the advantages and disadvantages of AMP-based nanomaterials currently under development for the treatment of bacterial infections in the literature, bringing inspiration and recommendations for their future design.

Institutions

Publication Details

Journal
Discover Nano
Published
2026-05-19
DOI
https://doi.org/10.1186/s11671-026-04534-5
Primary Topic
Antimicrobial Peptides and Activities
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antimicrobial peptides for bacterial infections and their biomedical applications

Discover Nano
Antimicrobial Peptides and Activities
article

Antimicrobial peptides for bacterial infections and their biomedical applications

article en

Abstract

Due to the rapid development of multidrug-resistant (MDR) bacteria due to the inappropriate use and misuse of antibiotics and the ineffective performance of antibiotics against refractory biofilm-associated infections (BRI), there is an urgent need for novel alternative antimicrobials and strategies to combat bacterial infections. Antimicrobial peptides (AMPs) have attracted considerable interest due to their potent activity against MDR pathogens and biofilm-associated infections, coupled with a substantially reduced risk of driving antimicrobial resistance-especially when employed as alternatives or adjuncts to conventional antibiotics. With the development of nanocarrier-based delivery strategies, AMP nanomaterials significantly improve the therapeutic effect of AMP by improving the hydrolytic stability, in vivo half-life, solubility, and reducing cytotoxicity and hemolysis of AMP. Distinct from previous reviews that primarily focus on AMP sequence engineering or generic nanocarrier types, this work adopts a clinically oriented framework organized by infection site-including pulmonary, bloodstream, gastrointestinal, chronic wound, and implant-associated infections. Key therapeutic outcomes reported in the literature are systematically compared, such as reductions in minimum inhibitory concentration (MIC), biofilm eradication efficiency, survival benefits in sepsis models, and wound closure kinetics. Formulation design strategies, administration routes, and the rational application of nanocarriers constructed from metallic elements, biocompatible polymers, and lipid-based architectures are discussed in the context of specific infectious microenvironments. By correlating the physicochemical properties of nanocarriers-such as surface charge, degradation profile, and release kinetics-with therapeutic performance across diverse infection models, this review also addresses the current limitations of AMP-based formulations in clinical applications. Overall, this review provides insights into the advantages and disadvantages of AMP-based nanomaterials currently under development for the treatment of bacterial infections in the literature, bringing inspiration and recommendations for their future design.

Discover NanoVol. 21(1)
Qingdao University (CN), Affiliated Hospital of Qingdao University (CN), Ocean University of China (CN)
Natural Science Foundation of Shandong Province
Openalex Percentile: Top 6%
Antimicrobial Peptides and Activities
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.